Advances in tumor-infiltrating B lymphocytes

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• T cell-mediated immunity dominates tumor immunotherapy research, often overlooking B cell contributions.
• Emerging evidence highlights the significant role of tumor-infiltrating B lymphocytes (TIL-B) in cancer treatment outcomes and prognostication.
• TIL-B influence standard treatments and immune checkpoint inhibition, suggesting potential for novel immunotherapeutic strategies.

Purpose of the Study:

• To review the current understanding of TIL-B in tumor immunotherapy.
• To elucidate the multifaceted roles of TIL-B in cancer progression and treatment response.
• To provide insights for developing TIL-B-based therapeutic approaches.

Main Methods:

• Literature review and synthesis of current research on TIL-B.
• Analysis of TIL-B heterogeneity and its functional implications (antitumor vs. protumor).
• Exploration of TIL-B interactions within the tumor microenvironment.

Main Results:

• TIL-B significantly impact therapeutic outcomes and patient prognosis.
• TIL-B populations exhibit heterogeneity, leading to both anti- and pro-tumor functions.
• Understanding TIL-B is essential for optimizing current immunotherapies and developing new ones.

Conclusions:

• TIL-B are critical players in tumor immunotherapy, impacting treatment efficacy and patient outcomes.
• The diverse functions of TIL-B necessitate further research to harness their potential as therapeutic targets.
• Comprehensive knowledge of TIL-B is vital for advancing cancer immunotherapy development.